Half-year results from generics business Hikma (HIK) won't include any impact from its recent billion-dollar acquisition of US rival Roxanne Laboratories. The group only announced the deal in late July, although it's likely the market will want more detail on how the transaction will transform Hikma's position in the US.
The deal, which is worth just under $1.2bn (£770m) plus 40m new Hikma shares - $2.65bn in total - is expected to make Hikma the sixth-largest generics company in the US by revenue. It will bring with it 88 new products across several fields, including oncology, respiratory, and controlled substances. There are also 89 projects under development that Hikma will hope to bring to the market.
There's no impact expected for the current financial year, but Hikma believes the deal will bump up earnings in 2016 and make a more significant in the years thereafter.
